O

    Ovid Therapeutics Inc (OVID)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.67
    -0.13 (-4.64%)

    Market Cap: $546.83M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(23/38)
    Avg Surprise
    -0.74%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.10 - $-0.08
    6 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.11-20.3%
    60d ago$-0.11-17.4%
    30d ago$-0.11-17.4%
    7d ago$-0.11-17.4%
    Current$-0.09
    Revenue Consensus
    $14200
    Range$0 - $132000
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.11 - $-0.05
    6 analysts
    Revenue Consensus
    $778090
    Range$637470 - $2M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.08$-0.10+20.00%Beat-33.3%
    Mar 26
    		$-0.12$-0.11-9.09%Miss+14.3%
    Dec 25
    		$0.06$-0.11+152.77%Beat+146.2%
    Sep 25
    		$-0.17$-0.15-13.33%Miss+15.0%
    Jun 25
    		$-0.06N/A+60.00%Beat-150.0%
    Mar 25
    		$-0.14$-0.13-7.69%Miss+17.6%
    Dec 24
    		$-0.13$-0.17+22.20%Beat+40.9%
    Sep 24
    		$-0.20$-0.23+13.04%Beat-25.0%
    Jun 24
    		$0.12$-0.24+150.00%Beat+166.7%
    Mar 24
    		$-0.17$-0.23+26.09%Beat+10.5%
    Dec 23
    		$-0.22$-0.05-340.00%Miss-37.5%
    Sep 23
    		$-0.16$-0.19+15.79%Beat+5.9%
    Jun 23
    		$-0.18$-0.21+14.29%Beat+14.3%
    Mar 23
    		$-0.19$-0.17-11.76%Miss+5.0%
    Dec 22
    		$-0.16$-0.18+11.11%Beat-60.0%
    Sep 22
    		$-0.17$-0.21+19.05%Beat+0.0%
    Jun 22
    		$-0.21$-0.25+16.00%Beat+8.7%
    Mar 22
    		$-0.20$-0.21+4.76%Beat-107.9%
    Dec 21
    		$-0.10$-0.16+37.50%Beat+70.6%
    Sep 21
    		$-0.17$-0.18+5.56%Beat+39.3%
    Jun 21
    		$-0.23$-0.16-43.75%Miss+43.9%
    Mar 21
    		$2.53$1.13+123.89%Beat+783.8%
    Dec 20
    		$-0.34$-0.31-9.68%Miss+2.9%
    Sep 20
    		$-0.28$-0.35+20.00%Beat+34.9%
    Jun 20
    		$-0.41$-0.35-17.14%Miss-20.6%
    Mar 20
    		$-0.37$-0.33-12.12%Miss+19.6%
    Dec 19
    		$-0.35$-0.39+10.26%Beat+32.7%
    Sep 19
    		$-0.43$-0.36-19.44%Miss+18.9%
    Jun 19
    		$-0.34$-0.40+15.00%Beat+35.8%
    Mar 19
    		$-0.46$-0.41-12.20%Miss+14.8%
    Dec 18
    		$-0.52$-0.55+5.45%Beat-15.6%
    Sep 18
    		$-0.53$-0.61+13.11%Beat-39.5%
    Jun 18
    		$-0.53$-0.61+13.11%Beat+7.0%
    Mar 18
    		$-0.54$-0.53-1.89%Miss+84.5%
    Dec 17
    		$-0.45$-0.41-9.76%Miss-
    Sep 17
    		$-0.38$-0.54+29.63%Beat-
    Jun 17
    		$-0.57$-0.48-18.75%Miss-
    Mar 17
    		$-3.48$-0.87-300.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-8.61EV/EBITDA-0.69x
    Price/FCF-9.63xFCF Yield-10.39%
    Profitability
    Profit Margin0.00%Operating Margin-2101.00%
    ROE-26.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio12.39xQuick Ratio12.39x
    Trading Statistics
    Beta0.23Avg Volume1.53M
    52-Week High$3.1052-Week Low$1.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.83
    SMA 20$2.75
    SMA 50$2.58
    SMA 200$2.17
    EMA 10$2.80
    EMA 20$2.74
    EMA 50$2.62
    EMA 200$2.18

    MACD

    Line: 0.08Signal: 0.09Hist: -0.01

    ADX

    ADX: 17.1+DI: 18.4-DI: 20.4

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down16.0
    PSAR$2.95

    Bollinger Bands

    Upper Band$3.01
    Lower Band$2.50
    %B Position1848%(Upper)
    Band Width0.33

    RSI (14-Day)

    Neutral
    48.5

    Momentum Oscillators

    Stoch %K71.2
    Stoch %D82.5
    Williams %R-53.8
    ROC (10d)-7.6%
    Momentum-0.22
    CCI (20d)-20.3
    MFI (14d)57.3

    Volatility Measures

    ATR (14d)$0.15(5.5%)
    StdDev (20d)0.13
    Hist Vol58.2%(High)

    Volume Flow

    VWAP$2.71
    OBV191.7M
    AD Line10.1M
    CMF (20d)0.269

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.9x
    VWMA (20d)$2.77

    Pivot Points

    R3$3.07
    R2$3.00
    R1$2.90
    Pivot Point$2.83
    S1$2.73
    S2$2.66
    S3$2.56

    Advanced Oscillators

    TSI16.24
    Ultimate Osc56.3
    KST136.71

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$733,000$0$718,000$132,000$6.27M$130,000$76,000$173,000$169,000$148,000$142,000$109,000
    Cost of Revenue$0$0$44,000$0$0$0N/A$0$0$0$401,392$0
    Gross Profit$733,000$0$718,000$132,000$6.27M$130,000$76,000$173,000$169,000$148,000$142,000$109,000
    Operating Expenses$16.43M$17.85M$13.01M$12.65M$11.35M$12.68M$10.80M$13.40M$20.69M$17.57M$18.33M$12.14M
    R&D$9.96M$11.18M$6.59M$5.87M$6.46M$6.66M$5.93M$7.86M$12.58M$10.40M$10.64M$5.33M
    SG&A$6.47M$6.67M$6.42M$6.79M$4.88M$6.02M$4.87M$5.54M$8.10M$7.17M$7.69M$6.80M
    Operating Income$-15,698,000$-17,846,000$-12,293,000$-12,523,000$-5,073,000$-12,550,000$-10,725,000$-13,226,000$-20,517,000$-17,417,000$-18,188,000$-12,029,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$780,000$0$0$0$0
    Income Before Tax$-15,009,000$-16,988,000$9.66M$-12,158,000$-4,684,000$-10,235,000$-9,254,000$-14,006,000$8.52M$-11,694,000$-15,322,000$-11,253,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-15,009,000$-16,988,000$9.66M$-12,158,000$-4,684,000$-10,235,000$-9,254,000$-14,006,000$8.52M$-11,694,000$-15,322,000$-11,253,000
    EBITDA$-14,675,000$-16,641,000$9.99M$-11,842,000$-4,291,000$-9,806,000$-8,812,000$-13,560,000$8.94M$-11,292,000$-14,920,000$-10,851,000
    EBIT$-15,009,000$-16,988,000$9.66M$-12,158,000$-4,684,000$-10,235,000$-9,254,000$-14,006,000$8.52M$-11,694,000$-15,321,000$-11,253,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OVID

    News

    Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades

    Jeffrey A. Rona, an affiliated stockholder of Ovid Therapeutics Inc. (OVID), has filed a Rule 144 notice to sell up to 325,000 shares of common stock, valued at $910,000, around August 24, 2026. This proposed sale follows previous Rule 144 sales made by Rona in mid-August. The transaction is expected to be executed through Morgan Stanley after a stock option exercise.

    Stock Titan•8/24/26•
    Somewhat-Bearish

    Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7

    Wedbush has reiterated its Buy rating for Ovid Therapeutics (OVID.US) and maintained a target price of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•8/22/26•
    Bullish

    What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

    Ovid Therapeutics (OVID) is identified as a strong momentum stock with a Zacks Rank #2 (Buy) and a Momentum Style Score of A. The article highlights OVID's impressive short-term and long-term price performance, significantly outperforming its industry and the S&P 500. Positive earnings estimate revisions further contribute to its strong outlook, suggesting it could be a fresh pick for investors seeking near-term growth.

    Yahoo Finance•8/18/26•
    Bullish

    Ovid Therapeutics (NASDAQ:OVID) Raised to Hold at Wall Street Zen

    Wall Street Zen has upgraded Ovid Therapeutics (NASDAQ:OVID) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with a target price of $5.71. The company recently reported a quarterly loss of $0.08 per share, outperforming expectations, and revenue significantly exceeded the consensus estimate. Institutional investors and hedge funds hold a substantial 72.24% of the stock.

    MarketBeat•8/15/26•
    Bullish

    Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics

    Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has disclosed a 6.3% ownership stake in Ovid Therapeutics Inc. as of June 30, 2026. This ownership, totaling 11,812,241 shares of common stock, is held through the Eventide Healthcare & Life Sciences Fund. Eventide holds sole voting and dispositive power over these shares, while Kuruvilla and John share voting and dispositive power.

    Stock Titan•8/15/26•
    Neutral

    Frequently Asked Questions About OVID

    Does OVID pay dividends?
    Ovid Therapeutics Inc (OVID) does not currently pay a regular dividend.
    What is OVID's market cap?
    Ovid Therapeutics Inc (OVID) has a market capitalization of $546.83M with a current stock price of $2.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In